MD SB415 | 2017 | Regular Session

Status

Spectrum: Partisan Bill (Democrat 24-0)
Status: Introduced on January 27 2017 - 25% progression, died in committee
Action: 2017-02-15 - Hearing 2/15 at 1:00 p.m.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Prohibiting a manufacturer or wholesale distributor from engaging in price gouging in the sale of an essential generic drug; requiring the Maryland Medical Assistance Program to notify the manufacturer of an essential generic drug and the Attorney General of a specified increase in the price of the essential generic drug under specified circumstances; requiring a manufacturer of an essential generic drug to submit a specified statement to the Attorney General within 20 days after receipt of a specified notice; etc.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Public Health - Essential Generic Drugs - Price Gouging - Prohibition

Sponsors


History

DateChamberAction
2017-02-15SenateHearing 2/15 at 1:00 p.m.
2017-01-27SenateFirst Reading Finance

Subjects


Maryland State Sources


Bill Comments

feedback